Tags

Type your tag names separated by a space and hit enter

Novel tuberculosis vaccines on the horizon.
Curr Opin Immunol. 2010 Jun; 22(3):374-84.CO

Abstract

Eleven new tuberculosis (TB) vaccines are in various phases of clinical trials. These include subunit vaccines to improve the current vaccine BCG, and recombinant BCG to substitute for BCG, both given pre-exposure to prevent active disease. A plethora of potential candidates have reached various stages of the pre-clinical development pipeline, some ready to enter Phase I clinical trial soon. A boost vaccine to top up the immunity of existing BCG is on the horizon and will have to suffice until a better candidate to replace BCG is ready. The live mutants of Mycobacterium tuberculosis show great promise, but face a myriad of regulatory challenges.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Parida SK
Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany. parida@mpiib-berlin.mpg.de
Kaufmann SH
No affiliation info available

MeSH

AnimalsBCG VaccineClinical Trials as TopicGuinea PigsHumansMiceMycobacterium tuberculosisTuberculosisTuberculosis VaccinesVaccinationVaccines, Subunit

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20471231

Citation

Parida, Shreemanta K., and Stefan H E. Kaufmann. "Novel Tuberculosis Vaccines On the Horizon." Current Opinion in Immunology, vol. 22, no. 3, 2010, pp. 374-84.
Parida SK, Kaufmann SH. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol. 2010;22(3):374-84.
Parida, S. K., & Kaufmann, S. H. (2010). Novel tuberculosis vaccines on the horizon. Current Opinion in Immunology, 22(3), 374-84. https://doi.org/10.1016/j.coi.2010.04.006
Parida SK, Kaufmann SH. Novel Tuberculosis Vaccines On the Horizon. Curr Opin Immunol. 2010;22(3):374-84. PubMed PMID: 20471231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel tuberculosis vaccines on the horizon. AU - Parida,Shreemanta K, AU - Kaufmann,Stefan H E, Y1 - 2010/05/12/ PY - 2010/03/17/received PY - 2010/04/15/revised PY - 2010/04/15/accepted PY - 2010/5/18/entrez PY - 2010/5/18/pubmed PY - 2010/10/5/medline SP - 374 EP - 84 JF - Current opinion in immunology JO - Curr Opin Immunol VL - 22 IS - 3 N2 - Eleven new tuberculosis (TB) vaccines are in various phases of clinical trials. These include subunit vaccines to improve the current vaccine BCG, and recombinant BCG to substitute for BCG, both given pre-exposure to prevent active disease. A plethora of potential candidates have reached various stages of the pre-clinical development pipeline, some ready to enter Phase I clinical trial soon. A boost vaccine to top up the immunity of existing BCG is on the horizon and will have to suffice until a better candidate to replace BCG is ready. The live mutants of Mycobacterium tuberculosis show great promise, but face a myriad of regulatory challenges. SN - 1879-0372 UR - https://www.unboundmedicine.com/medline/citation/20471231/Novel_tuberculosis_vaccines_on_the_horizon_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0952-7915(10)00070-1 DB - PRIME DP - Unbound Medicine ER -